Effects of short-term intensive glycemic control on insulin, glucagon, and glucagon-like peptide-1 secretion in patients with Type 2 diabetes

Journal of Endocrinological Investigation

Volumn 36, Issue 9, 2013, Pages 734-738

  Shimodaira, M ^a,b,c   Muroya, Y ^c   Kumagai, N ^c   Tsuzawa, K ^c   Honda, K ^c  

^a Iida Municipal Hospital   (Japan)

^b NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c TOKYO METROPOLITAN HIROO HOSPITAL   (Japan)

Author keywords

Glucagon; Glucagon like peptide 1; Intensive insulin therapy

Indexed keywords

C REACTIVE PROTEIN; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; IMMUNOREACTIVE INSULIN; INSULIN;

ADULT; ARTICLE; BLOOD PRESSURE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GLUCAGON BLOOD LEVEL; GLUCAGON RELEASE; GLYCEMIC CONTROL; HUMAN; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN TREATMENT; INTENSIVE INSULIN THERAPY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE; SHORT COURSE THERAPY; TEST MEAL;

ADULT; AGED; AGED, 80 AND OVER; BLOOD GLUCOSE; C-PEPTIDE; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INSULIN; MALE; MIDDLE AGED;

EID: 84891688411     PISSN: 03914097     EISSN: 17208386     Source Type: Journal    
DOI: 10.3275/8934     Document Type: Article

References (28)

1. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006, 355: 2427-43
2. Weng J, Li Y, Xu W, et al. Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet 2008, 371: 1753-60.
3. Shah P, Vella A, Basu A, Basu R, Schwenk WF, Rizza RA. Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab 2000, 85: 4053-9.
4. Reaven GM, Chen YD, Golay A, Swislocki AL, Jaspan JB. Documentation of hyperglucagonemia throughout the day in nonobese and obese patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1987, 64: 106-10.
5. Toft-Nielsen MB, Madsbad S, Holst JJ. Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. Diabetes Care 1999, 22: 1137-43.
6. Vilsboll T, Krarup T, Deacon CF, Madsbad S, Holst JJ. Reduced post-prandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 2001, 50: 609-13.
7. Alvarsson M, Sundkvist G, Lager I, et al. Beneficial effects of insulin versus sulphonylurea on insulin secretion and metabolic control in recently diagnosed type 2 diabetic patients. Diabetes Care 2003, 26: 2231-7.
8. Ryan EA, Imes S, Wallace C. Short-term intensive insulin therapy in newly diagnosed type 2 diabetes. Diabetes Care 2004, 27: 1028-32.
9. Li Y, Xu W, Liao Z, et al. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of beta-cell function. Diabetes Care 2004, 27: 2597-602.
10. Chen HS, Wu TE, Jap TS, Hsiao LC, Lee SH, Lin HD. Beneficial effects of insulin on glycemic control and beta-cell function in newly diagnosed type 2 diabetes with severe hyperglycemia after short-term intensive insulin therapy. Diabetes Care 2008, 31: 1927-32.
11. Retnakaran R, Yakubovich N, Qi Y, Opsteen C, Zinman B. The response to short-term intensive insulin therapy in type 2 diabetes. Diabetes Obes Metab 2010, 12: 65-71.
12. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28: 412-9.
13. Levy JC, Matthews DR, Hermans MP. Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care 1998, 21: 2191-2.
14. De Rossi A, Masiero S, Giaquinto C, et al. Dynamics of viral replication in infants with vertically acquired human immunodeficiency virus type 1 infection. J Clin Invest 1996, 97: 323-30.
15. Vilsboll T, Krarup T, Sonne J, et al. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. J Clin Endocrinol Metab 2003, 88: 2706-13.
16. Sherwin RS, Fisher M, Hendler R, Felig P. Hyperglucagonemia and blood glucose regulation in normal, obese and diabetic subjects. N Engl J Med 1976, 294: 455-61.
17. Mitrakou A, Kelley D, Mokan M, et al. Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance. N Engl J Med 1992, 326: 22-9.
18. Franklin I, Gromada J, Gjinovci A, Theander S, Wollheim CB. Beta-cell secretory products activate alpha-cell ATP-dependent potassium channels to inhibit glucagon release. Diabetes 2005, 54: 1808-15.
19. Ding WG, Renstrom E, Rorsman P, Buschard K, Gromada J. Glucagon-like peptide I and glucose-dependent insulinotropic polypeptide stimulate Ca2+-induced secretion in rat alpha-cells by a protein kinase Amediated mechanism. Diabetes 1997, 46: 792-800.
20. Yoon KH, Ko SH, Cho JH, et al. Selective beta-cell loss and alpha-cell expansion in patients with type 2 diabetes mellitus in Korea. J Clin Endocrinol Metab 2003, 88: 2300-8.
21. Bosco D, Armanet M, Morel P, et al. Unique arrangement of alpha-and beta-cells in human islets of Langerhans. Diabetes 2010, 59: 1202-10.
22. Henquin JC, Rahier J. Pancreatic alpha cell mass in European subjects with type 2 diabetes. Diabetologia 2011, 54: 1720-5.
23. Juhl CB, Porksen N, Pincus SM, Hansen AP, Veldhuis JD, Schmitz O. Acute and short-term administration of a sulfonylurea (gliclazide) increases pulsatile insulin secretion in type 2 diabetes. Diabetes 2001, 50: 1778-84.
24. Wajchenberg BL. beta-cell failure in diabetes and preservation by clinical treatment. Endocr Rev 2007, 28: 187-218.
25. Gleason CE, Gonzalez M, Harmon JS, Robertson RP. Determinants of glucose toxicity and its reversibility in the pancreatic islet beta-cell line, HIT-T15. Am J Physiol Endocrinol Metab 2000, 279: E997-1002.
26. McFarlane SI, Chaiken RL, Hirsch S, Harrington P, Lebovitz HE, Banerji MA. Near-normoglycaemic remission in African-Americans with Type 2 diabetes mellitus is associated with recovery of beta cell function. Diabet Med 2001, 18: 10-6.
27. Chan JC, Malik V, Jia W, et al. Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA 2009, 301: 2129-40.
28. Hansen TK, Thiel S, Wouters PJ, Christiansen JS, Van den Berghe G. Intensive insulin therapy exerts antiinflammatory effects in critically ill patients and counteracts the adverse effect of low mannose-binding lectin levels. J Clin Endocrinol Metab 2003, 88: 1082-8.